CIGNA (CI) Getting Somewhat Positive Press Coverage, Accern Reports
Press coverage about CIGNA (NYSE:CI) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CIGNA earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the health services provider an impact score of 46.101080208394 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- CIGNA Co. (CI) Director Sells $43,604.16 in Stock (americanbankingnews.com)
- John M. Murabito Sells 28,037 Shares of CIGNA Co. (CI) Stock (americanbankingnews.com)
- An expat’s introduction to healthcare in Norway (thelocal.no)
- From a supermarket loyalty scheme to funeral insurance | Stuff.co.nz – Stuff.co.nz (stuff.co.nz)
- Cigna CEO on CVS-Aetna Merger, M&A, Health Care – Presented by: The Aol. On Network (nasdaq.com)
Shares of CIGNA (NYSE CI) traded up $2.50 during midday trading on Friday, hitting $213.39. The stock had a trading volume of 1,150,000 shares, compared to its average volume of 1,240,000. CIGNA has a twelve month low of $133.52 and a twelve month high of $213.73. The stock has a market capitalization of $52,610.00, a P/E ratio of 23.37, a price-to-earnings-growth ratio of 1.44 and a beta of 0.51. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.39 and a current ratio of 0.39.
Several analysts have recently weighed in on CI shares. Jefferies Group upped their price objective on CIGNA from $221.00 to $231.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Zacks Investment Research lowered CIGNA from a “buy” rating to a “hold” rating in a report on Friday, November 10th. ValuEngine upgraded CIGNA from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Piper Jaffray Companies restated a “buy” rating and issued a $191.00 price objective on shares of CIGNA in a report on Sunday, September 17th. Finally, BMO Capital Markets began coverage on CIGNA in a report on Monday, October 16th. They set a “market perform” rating and a $210.00 target price for the company. Three analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $205.18.
In related news, Director William D. Zollars sold 212 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $205.68, for a total transaction of $43,604.16. Following the transaction, the director now directly owns 13,500 shares of the company’s stock, valued at $2,776,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Mary T. Hoeltzel sold 575 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $197.03, for a total value of $113,292.25. Following the transaction, the chief accounting officer now directly owns 2,499 shares in the company, valued at $492,377.97. The disclosure for this sale can be found here. Insiders have sold 63,185 shares of company stock worth $12,789,459 over the last three months. 1.30% of the stock is owned by insiders.
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.